Evidence map›Paper›PMID 35917745›Full record

ArticleMultiple sclerosis and related disorders2022

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.

Steve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, Liesbet M Peeters, Lotte Geys, Tina Parciak, Anne Helme, Jan Hillert, Yves Moreau, Gilles Edan and 34 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors at 20 institutions in 13 countries.

Steve Simpson-YapCORe, Department of Medicine, The University of Melbourne, Australia; Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia; Menzies Institute for Medical Research, University of Tasmania, Australia. Electronic address: steve.simpsonyap@unimelb.edu.au.
Ashkan PirmaniUniversity MS Center, (UMSC) Hasselt/Pelt, Belgium; Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agoralaan Building D, 3590, Diepenbeek, Belgium; ESAT-STADIUS, KU Leuven, Belgium.
Edward De BrouwerESAT-STADIUS, KU Leuven, Belgium.
Liesbet M PeetersUniversity MS Center, (UMSC) Hasselt/Pelt, Belgium; Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agoralaan Building D, 3590, Diepenbeek, Belgium.
Lotte GeysBiomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agoralaan Building D, 3590, Diepenbeek, Belgium.
Tina ParciakUniversity MS Center, (UMSC) Hasselt/Pelt, Belgium; Biomedical Research Institute - Data Science Institute, Hasselt University, Belgium; Biomedical Research Institute (BIOMED), Hasselt University, Agoralaan Building C, 3590 Diepenbeek, Belgium; Data Science Institute (DSI), Hasselt University, Agoralaan Building D, 3590, Diepenbeek, Belgium.
Anne HelmeMS International Federation, United Kingdom.
Jan HillertDepartment of Clinical Neuroscience, Swedish MS Registry, Sweden; Karolinska Institutet, Sweden.
Yves MoreauESAT-STADIUS, KU Leuven, Belgium.
Gilles EdanDepartment of Neurology, CHU Pontchaillou, France.
Tim SpelmanDepartment of Clinical Neuroscience, Swedish MS Registry, Sweden; Karolinska Institutet, Sweden.
Sifat SharminCORe, Department of Medicine, The University of Melbourne, Australia.
Robert McBurneyiConquerMS People-Powered Research Network, Accelerated Cure Project for MS, United States of America.
Hollie SchmidtiConquerMS People-Powered Research Network, Accelerated Cure Project for MS, United States of America.
Arnfin BergmannNeuroTransData Study Group, NeuroTransData, Germany.
Stefan BrauneNeuroTransData Study Group, NeuroTransData, Germany.
Alexander StahmannGerman MS-Register by the National MS Society, MS Forschungs- und Projektentwicklungs-gGmbH, Germany.
Rodden MiddletonUK MS Register, Swansea University, United Kingdom.
Amber SalterCOViMS, United States of America; Division of Biostatistics, Washington University in St Louis, United States of America.
Bruce BeboCOViMS, United States of America.
Anneke van der WaltDepartment of Neuroscience, Central Clinical School, Monash University, Australia.
Helmut ButzkuevenDepartment of Neuroscience, Central Clinical School, Monash University, Australia.
Serkan OzakbasAmiri Hospital, Kuwait.
Rana KarabudakDepartment of Neurology, University of Hacettepe, Turkey.
Cavit BozDepartment of Neurology, Karadeniz Technical University, Turkey.
Raed AlroughaniDokuz Eylul University, Turkey.
Juan I RojasNeurology Department, Hospital Universitario de CEMIC, Argentina; RELACOEM, Argentina.
Ingrid van der MeiThe Australian MS Longitudinal Study, Menzies Institute for Medical Research, University of Tasmania, Australia.
Guilherme Sciascia do OlivalABEM - Brazilian MS Patients Association, Brazil.
Melinda MagyariThe Danish Multiple Sclerosis Registry, Departement of Neurology, University Hospital Rigshospitalet, Denmark.
Ricardo AlonsoRELACOEM, Argentina; Multiple Sclerosis University Center, Ramos Mejia Hospital - EMA, Argentina.
Richard NicholasUK MS Register, Swansea University, United Kingdom; Imperial College London, United Kingdom; Swansea University, United Kingdom.
Anibal ChertcoffMS and Demyelinating Diseases. Hospital Británico de Buenos Aires, EMA, Argentina.
Ana ZabalzaServei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona, Spain.
Georgina ArrambideServei de Neurologia-Neuroimmunologia. Centre d'Esclerosi Múltiple de Catalunya, (Cemcat). Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari. Universitat Autònoma de Barcelona, Spain.
Nupur NagNeuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Australia.
Annabel Descampsicometrix, Belgium.
Lars Costersicometrix, Belgium.
Ruth DobsonQueen Mary University London, United Kingdom.
Aleisha MillerImperial College London, United Kingdom.
Paulo RodriguesQMENTA, Inc., Spain.
Vesna PrčkovskaQMENTA, Inc., Spain.
Giancarlo ComiCasa di Cura del Policlinico and Università Vita Salute San Raffaele, Italy.
Tomas KalincikCORe, Department of Medicine, The University of Melbourne, Australia; MS Centre, Department of Neurology, Royal Melbourne Hospital, Australia.
National MS Center MelsbroekIcometrix (Belgium) · BEKarolinska Institutet · SEKU Leuven · BEMonash University · AUResearch Network (United States) · USSwansea University · GBThe University of Melbourne · AUUniversitat Autònoma de Barcelona · ESUniversity of Tasmania · AUAmiri Hospital · KWBrazilian Medical Association · BRDokuz Eylül University · TRHacettepe University · TRHasselt University · BEHôpital Pontchaillou · FRHospital Británico de Buenos Aires · ARHospital Ramos Mejía · ARHospital Universitario Austral · ARImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.

resultsAmong 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.

conclusionsIn comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.

Indexed as

COVID-19Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAcetatesDimethyl FumarateGlatiramer AcetateHumansImmunosuppressive AgentsInterferon-betaAcetatesDimethyl FumarateGlatiramer AcetateImmunosuppressive AgentsInterferon-beta

Identifiers

PMID35917745
PMCPMC9310378
OpenAlexW4287512401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.